Role of GPRC5D in R/R MM Patients
January 18th 2024An expert briefly reviews the role of GPRC5C-targeting bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM) following four previous lines of therapy, comparing its efficacy and characteristics with other treatment options like BCMA and CAR-T therapies. She also provides insights into the benefits, risks, and potential challenges related to the access and utilization of GPRC5D-targeting bispecifics, providing a comprehensive overview of considerations in the advanced R/R MM treatment landscape.
Selecting The Appropriate Treatment in Transplant-Eligible Newly Diagnosed MM
January 30th 2023A brief discussion how to select the appropriate treatment strategy in transplant-eligible newly diagnosed myeloma and whether there is a role for minimal residual disease in assessing response and treatment duration.
Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma
November 17th 2022Dr Krina Patel presents the case of a relatively young patient with relapsed multiple myeloma, and Dr Caitlin Costello shares her approaches to treating relapsed/refractory multiple myeloma in her clinical practice.